After my Master degree in the field of cancer cell biology and therapeutics, I joined IMPRS-MCB to study Epigenetics, particularly dosage compensation. In fact, during embryonic development, organisms are challenged with regulating gene dosage for proper development and organogenesis. In mammals, most of the genes are expressed from both paternal and maternal alleles; however, there are several genes that are reported to be allele specifically expressed. Interestingly, X chromosome inactivation (XCI) and genomic imprinting are among the most studied cases of monoallelic gene expression phenomena.
In my PhD project, I am trying to understand the role of male-specific lethal (MSL) and non-specific-lethal (NSL) complexes in dosage compensation, mainly XCI.
Hmadi R, Nasr R, El-Eit R, Iskandarani A, Jabbour M, Zaatari G, Mahon F, Pisano C, Darwiche N (2014) ST1926, an orally active synthetic retinoid, induces apoptosis in chronic myeloid leukemia cells and prolongs survival in a murine model. Int J Cancer doi:10.1002/ijc.29407
Saliba J, Deleuze-Masquefa C, Iskandarani A, El Eit R, Hmadi R, Mahon FX, Bazarbachi A, Bonnet PA, Nasr R (2014) EAPB0503, a novel imidazoquinoxaline derivative, inhibits growth and induces apoptosis in chronic myeloid leukemia cells. Anticancer Drugs 25 (6):624-632.